You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

The 2DR Era

Explore dolutegravir based, 2-drug regimens for your diverse patient needs.

Image of pill may not reflect the actual size.
Times are changing | 2DR Era

No one should take more medicines than they need

2DR: Meeting a clinical need

The HIV treatment landscape has changed dramatically over the past 30 years, with each decade serving as a foundation for the next to build upon. Today marks the beginning of the next era in HIV therapy...THE 2DR ERA. 1

  • A 20-year-old starting a 3-drug regimen may be on therapy for nearly 6 DECADES, which translates to MORE THAN 60,000 DOSES of individual medications 4
Timeline of HIV Treatment

See how a 2DR can benefit your patients

*Juluca is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI. 5

^Dovato is indicated for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 6

DDIs=drug-drug interactions.


  1. A timeline of HIV/AIDS. Accessed January 2021
  2. Llibre JM, et al. J Antimicrob Chemother. 2016;71:856-861.
  3. Antiretroviral drugs used in the treatment of HIV infection. Accessed January 2021
  4. The Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2017;4:e349-e356.
  5. Juluca Summary of Product Characteristics. Available from:, last accessed January 2021
  6. Dovato Summary of Product Characteristics. Available from: last accessed January 2021

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.